NCT03714594View on ClinicalTrials.gov

Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 24, 2018

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
Type2 Diabetes Mellitus
Interventions
DRUG

Dapagliflozin 10mg

Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine.\[

DRUG

Saxagliptin 5mg

Inhibits DPP-4 and slows inactivation of incretin hormones, thereby increasing blood concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus

DRUG

Saxagliptin 5mg + Dapagliflozin 10 mg

Please see Intervention 1 and 2

Trial Locations (1)

56124

Department of Endocrinology and Metabolism, University of Pisa, Pisa

All Listed Sponsors
lead

University of Pisa

OTHER

NCT03714594 - Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2. | Biotech Hunter | Biotech Hunter